Article
BeiGene nabs another PD-1 approval in China. Can partner Novartis carry the success to US and Europe?
Rating:
0.0
Views:
71
Likes:
1
Library:
1
With the lack of success of its PD-1/L1 candidate spartalizumab, Novartis last year decided to buy its way into the arena. | BeiGene has won approval in China for tislelizumab as a treatment for second-line patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the eighth approval in the last three years in its home country for the drug, which has yet to gain a nod outside of China.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value